COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Clinical-stage Aiolos Bio develops AIO-001, a humanized anti‑TSLP monoclonal antibody with extended half-life enabling twice‑yearly dosing, in Phase 2 asthma trials and exploring inflammatory indications; holds ex‑China rights.
